Harvard Management Company’s Relay Therapeutics RLAY Stock Holding History

Harvard Management Company’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-541,124	Closed	-$8.91M	–	46
2023 Q1	$8.91M	Hold	541,124	–	–	0.94%	18
2022 Q4	$8.08M	Hold	541,124	–	–	1%	17
2022 Q3	$12.1M	Hold	541,124	–	–	1.51%	10
2022 Q2	$9.06M	Hold	541,124	–	–	1.05%	14
2022 Q1	$16.2M	Hold	541,124	–	–	1.63%	8
2021 Q4	$16.6M	Hold	541,124	–	–	1.56%	11
2021 Q3	$17.1M	Hold	541,124	–	–	1%	14
2021 Q2	$19.8M	Hold	541,124	–	–	1.14%	17
2021 Q1	$18.7M	Hold	541,124	–	–	1.05%	16
2020 Q4	$22.5M	Hold	541,124	–	–	1.22%	12
2020 Q3	$23M	Buy	+541,124	New	+$20.6M	1.27%	10

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Harvard Management Company's RLAY Position: Q2 2023 in Review

Harvard Management Company sold out of Relay Therapeutics (RLAY) in Q2 2023, closing a stake of 541,124 shares — an estimated $8.91M sold.

Harvard Management Company first reported a position in RLAY in Q3 2020 and held it in 11 quarters. The position peaked at $23M in Q3 2020. 161 funds tracked by Wall St. Rank hold RLAY as of Q2 2023.

Harvard Management Company reported no remaining Relay Therapeutics position as of Q2 2023 after selling out during the quarter.
Harvard Management Company sold 541,124 Relay Therapeutics shares in Q2 2023, an estimated $8.91M.
Harvard Management Company first reported a position in Relay Therapeutics in Q3 2020 and held it in 11 quarters.
Harvard Management Company's Relay Therapeutics position peaked at $23M in Q3 2020.
161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2023.

Based on Harvard Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.